Tempus Expands Bristol Myers Squibb Collaboration in Multiyear Agreement
Bristol Myers Squibb will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification and drug-target discovery.
Story updates
01:01:09 PM UTC
SquawkNews
Tempus AI announced a multi-year agreement with Bristol Myers Squibb to license de-identified multimodal oncology data through 2031 and provide access to its Lens AI platform for oncology R&D.Material DetailsContext by AI AnalystThis extends a known Tempus-BMS relationship, reinforcing Tempus’ push…